Price Alert

Kezar Life Sciences Inc. (KZR)

NASDAQ: KZR · Real-Time Price · USD

4.21

-0.09 (-2.09%)

At close: Oct 16, 2025, 3:59 PM

-2.09% (1D)

Bid	3.93
Market Cap	30.83M
Revenue (ttm)	n/a
Net Income (ttm)	-70.79M
EPS (ttm)	-9.7
PE Ratio (ttm)	-0.43
Forward PE	-0.72
Analyst	Hold
Dividends	n/a

Ask	4.6
Volume	73,697
Avg. Volume (20D)	42,845
Open	4.28
Previous Close	4.30
Day's Range	4.10 - 4.47
52-Week Range	3.53 - 8.60
Beta	0.62
Ex-Dividend Date	n/a

About KZR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol KZR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for KZR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

News

10 hours ago · businesswire.com

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet n...

4 weeks ago · zacks.com

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy

Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · businesswire.com

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...